Dergiler / Koşuyolu Heart Journal / 2015 / Cilt: 18 - Sayı: 3
Kararlı Anjina Pektorisli Hastalarda Trimetazidin Tedavisinin Lipoprotein İlişkili Fosfolipaz A2 Düzeyi ve Egzersiz Parametreleri Üzerine Etkisi
- Sayfa
- 126–129
- DOI
- —
Özet
<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"ＭＳ 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-alt:"Minion Pro"; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"ＭＳ 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"ＭＳ 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"ＭＳ 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Giriş: Kararlı anjina pektorisli hastalarda, metabolik bir anti-iskemik ilaç olan trimetazidin (TMZ) tedavisinin risk faktörü olarak kabul edilen lipoprotein ilişkili fosfolipaz A2 (Lp-PLA2) düzeyi ve egzersiz parametreleri üzerine etkisi araştırıldı. Hastalar ve Yöntem: Egzersiz testi pozitif olan kararlı anjina pektorisli 30 hasta (ort. yaş 62.1 ± 8.3; dağılım 47-77) çalışmaya alındı. Trimetazidin tedavisi öncesinde Lp-PLA2 düzeyleri ölçüldü; 12 haftalık TMZ tedavisi sonrasında egzersiz testi ve Lp-PLA2 ölçümleri tekrarlandı. Bulgular: Trimetazidin tedavisi sonrasında Lp-PLA2 düzeyleri anlamlı düşüş (p= 0.006), egzersiz iş yükü anlamlı artış (p= 0.048) gösterdi. Sonuç: Trimetazidin tedavisi kardiyak metabolizma değişikliği sonucu serbest oksijen radikal oluşumunu ve enflamasyonu azaltarak Lp-PLA2 düzeyinde anlamlı düşüş sağlamaktadır. Bu bulgu, egzersiz parametrelerindeki iyileşmelerle birlikte, TMZ tedavisinin kararlı anjina pektorisli hastaların prognozunda olumlu katkı sağlayabileceğini göstermektedir.
Abstract
<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"ＭＳ 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"ＭＳ 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-alt:"Minion Pro"; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"ＭＳ 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"ＭＳ 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"ＭＳ 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Introduction: We examined the clinical effectiveness of trimetazidine (TMZ), a metabolic anti-ischemic agent, on lipoprotein-associated phospholipase A2 (Lp-PLA2) levels, which is considered a risk factor for cardiovascular events, and on exercise parameters in patients with stable angina pectoris (SAP). Patients and Methods: The study included 30 patients (mean age 62.1 ± 8.3 years; range 47 to 77 years) with SAP and a positive exercise test result. Serum Lp-PLA2 levels were measured at baseline. Exercise testing and Lp-PLA2 measurements were repeated after at least 12 weeks of TMZ treatment. Results: After TMZ treatment, Lp-PLA2 levels decreased significantly (p= 0.006), and workload increased significantly (p= 0.048). Conclusion: Trimetazidine treatment reduces serum Lp-PLA2 levels via shifting cardiac metabolism, resulting in decreased production of free oxygen radicals and inflammation. This finding, together with improvements in exercise test parameters, suggests that TMZ may have a beneficial effect on the prognosis of patients with SAP.